




Title	Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes
Author(s)	Takahashi, Kiyohiko; Cho, Kyu Yong; Nakamura, Akinobu; Miya, Aika; Miyoshi, Arina; Yamamoto, Chiho; Nomoto, Hiroshi; Niwa, Hirokatsu; Takahashi, Kiyohito; Manda, Naoki; Kurihara, Yoshio; Aoki, Shin; Ito, Yoichi M; Atsumi, Tatsuya; Miyoshi, Hideaki
Citation	Journal of Diabetes Investigation, 10(2), 429-438 <a href="https://doi.org/10.1111/jdi.12913">https://doi.org/10.1111/jdi.12913</a>
Issue Date	2019-03
Doc URL	<a href="http://hdl.handle.net/2115/72899">http://hdl.handle.net/2115/72899</a>
Rights(URL)	<a href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</a>
Type	article
Additional Information	There are other files related to this item in HUSCAP. Check the above URL.
File Information	jdi12913-sup-0001-figs1-2.pdf (Supporting Information)




[Instructions for use](#)

**sulfonylurea dose**




**age**



**Supplementary Figure1**

ROC for the cut-off value of sulfonylurea dose and age to identify non-exacerbation of HbA1c in the Discontinuation group.



### Supplementary Figure 2

Incidence of hypoglycaemic episodes in the Discontinuation group compared with the Low-dose group during the study period.